3 reports of this reaction
1.4% of all LIDOCAINE HCL, MENTHOL reports
#9 most reported adverse reaction
COGNITIVE DISORDER is the #9 most commonly reported adverse reaction for LIDOCAINE HCL, MENTHOL, manufactured by Amazon.com Services LLC. There are 3 FDA adverse event reports linking LIDOCAINE HCL, MENTHOL to COGNITIVE DISORDER. This represents approximately 1.4% of all 208 adverse event reports for this drug.
Patients taking LIDOCAINE HCL, MENTHOL who experience cognitive disorder should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
COGNITIVE DISORDER is a less commonly reported adverse event for LIDOCAINE HCL, MENTHOL, but still significant enough to appear in the safety profile.
In addition to cognitive disorder, the following adverse reactions have been reported for LIDOCAINE HCL, MENTHOL:
The following drugs have also been linked to cognitive disorder in FDA adverse event reports:
COGNITIVE DISORDER has been reported as an adverse event in 3 FDA reports for LIDOCAINE HCL, MENTHOL. This does not prove causation, but indicates an association observed in post-market surveillance data.
COGNITIVE DISORDER accounts for approximately 1.4% of all adverse event reports for LIDOCAINE HCL, MENTHOL, making it a notable side effect.
If you experience cognitive disorder while taking LIDOCAINE HCL, MENTHOL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.